The $150m venture financing of WuXi Diagnostic Investment (Cayman) was the medical devices industry’s top venture financing deal as total deals worth $1.22bn were announced globally in February 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 21.8% over the previous month of $1.56bn and a drop of 15.9% when compared with the last 12-month average, which stood at $1.45bn.
Comparing venture financing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $825.82m. At the country level, the US topped the list in terms of deal value at $811.82m.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of venture financing deals activity in February 2021 was the US with 40 deals, followed by the China with 14 and the UK with five.
In 2021, as of February, medical devices venture financing deals worth $2.78bn were announced globally, marking an increase of 28.9% year on year.
medical devices industry venture financing deals in February 2021: Top deals
The top five medical devices industry venture financing deals accounted for 42.2% of the overall value during February 2021.
The combined value of the top five medical devices venture financing deals stood at $516m, against the overall value of $1.22bn recorded for the month.
The top five medical devices industry venture financing deals of February 2021 tracked by GlobalData were:
1) ABC International, CCBI Tech Venture, Shiyu Capital Group, Sunland Capital, Thermo Fisher Scientific and YF Capital’s $150m venture financing of WuXi Diagnostic Investment (Cayman)
2) The $105m venture financing of Truvian Sciences by DNS Capital, General Catalyst Partners, Glen Tullman, GreatPoint Ventures, TYH Ventures, Wasson Enterprise and Wittington Ventures
3) Catalio Capital Management, Cowen Healthcare Investments, Innovatus Capital Partners, Kern Capital Management, New Enterprise Associates, Northpond Ventures, PFM Health Sciences, Rock Springs Capital Management, Sands Capital Management, Vensana Capital and Windham Venture Partners’ $103m venture financing of Personal Genome Diagnostics
4) The $90m venture financing of Hyperfine Research by Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans
5) Ally Bridge Group and Northpond Ventures’ venture financing of Syapse for $68m.